Editor's Pick: The week ahead....
(RENE.L) ReNeuron Group PLC Buy/Sell
Add to portfolio Set Alert Level 2 Desktop Trader
Summary
|
|
|||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||
| Date/Time | Headline | Source |
|---|---|---|
| 16-11-09 | RNS |
|
|
RNS Number : 5315C ReNeuron Group plc 16 November 2009
PRESS RELEASE ReNeuron presents positive pre-clinical efficacy data with ReN009 stem cell therapy for peripheral arterial disease at leading US scientific conference Guildford, UK, 16 November 2009: ReNeuron Group plc (LSE: RENE.L) announces further positive pre-clinical efficacy data with its ReN009 stem cell therapy for peripheral arterial disease (PAD). PAD is a chronic and debilitating disease that progressively restricts blood flow in the limbs, causing cramping, chronic pain and in extreme cases, loss of limb. PAD is commonly associated with other conditions such as diabetes, obesity and stroke. At least 1 in 20 people over the age of 55 have some degree of PAD and it becomes more common with increasing age. The research was conducted by Professor Paolo Madeddu, Chair of Experimental Cardiovascular Medicine and colleagues at the Bristol Heart Institute, University of Bristol, UK, and builds on earlier preliminary work conducted by that group. In two studies, the researchers tested ReNeuron's lead CTX neural stem cell line, via intramuscular injection, in a recognised murine hind limb ischaemia model. A range of doses were used across the studies, from 3,000 to 3 million cells per treatment. A significant and dose-dependant recovery of blood flow to the ischaemic limb was seen as soon as three days after ischaemia, with significantly increased revascularisation of the damaged tissue after 21 days, as measured by increased capillary and arteriole density. The results of the above studies were presented by poster at the American Heart Association Scientific Sessions 2009 in Orlando, Florida, running from 14-18 November. An AHA Scientific Council travel stipend has been awarded to the Bristol team poster presenter in recognition of the scientific excellence of the abstract submitted to the Scientific Sessions. ReNeuron is developing its ReN009 therapy as an allogeneic (non-patient specific) stem cell treatment for late-stage PAD, or critical limb ischaemia, in diabetic patients for whom PAD is a side-effect of their diabetes. Further pre-clinical studies are currently in progress with ReN009, focusing on diabetic models and utilising the newly-developed frozen formulation of the CTX cell line which will be used in future clinical trials. The results of these further studies will be reported in early 2010. In the meantime, ReNeuron has scheduled meetings within the next month with both the UK Medicines and Healthcare Regulatory Agency (MHRA) and the UK Gene Therapy Advisory Committee (GTAC) in order to discuss and agree certain aspects of the late pre-clinical development plan for the ReN009 therapy. Equivalent meetings are also planned with regulatory authorities in other territories, including the US, ahead of initial clinical trials expected to commence in 2011. Commenting on the results of the study, Professor Madeddu said: "We are excited by these latest results using the CTX stem cell line, where we have successfully replicated, in a dose-dependent way, the results of a promising initial study in a recognised hind limb ischaemia model. We see real clinical potential in this cell line in ischaemia, where the angiogenic properties of the cell line appear to play a significant role in restoring blood flow in the affected region." Dr John Sinden, Chief Scientific Officer of ReNeuron, said: "The data from these studies clearly demonstrate the potency of our lead CTX stem cell line in models of ischaemia. With the ReN009 therapy, we aim to translate this potential towards a clinical setting in diabetic patients with critical limb ischaemia as a key objective for ReNeuron over the coming months. In order to achieve this, we will be greatly assisted by the very significant data package regarding safety and product quality that already exists for the CTX cell line, generated during the pre-clinical development of our ReN001 therapy for disabled stroke patients." Enquiries:
Michael Hunt, Chief Executive Officer
Dr John Sinden, Chief Scientific Officer
Jonathan Birt, Susan Quigley
Simon Leathers
Alastair Stratton, Tim Graham
About the Bristol Heart Institute and the University of Bristol The Bristol Heart Institute is made up of over 200 researchers and clinicians, from eight different departments in the University of Bristol, spanning three faculties, and from associated Bristol NHS Trusts. Research income is generated from grants, with the British Heart Foundation being the Institute's main funder. As well as improving collaboration between scientists and clinicians within the Institute, the aim is to communicate research findings to the public. Further information on research at the Bristol Heart Institute can be found at www.bris.ac.uk/bhi. The University of Bristol is consistently ranked among the leaders in UK higher education. According to The Times, it is among the top 40 universities in the world. Research-intensive and with an international reputation for quality and innovation, the University has 15,000 students from over 100 countries, together with more than 5,500 staff. In terms of the number of applications per undergraduate place, Bristol is arguably the most popular university in the country. The University was founded in 1876 and was granted its Royal Charter in 1909. It was the first university in England to admit women on the same basis as men. It is located in the heart of the city from which it grew, but is now a significant player on the world stage as well as a major force in the economic, social and cultural life of Bristol and South West England. The overall quality of the University's teaching emerged as 'excellent' from the rigorous, independent assessment process. Its record as a research institution is at least as distinguished, with 78 per cent of its departments judged as world class or internationally excellent. The University is also recognised as a leading centre for the exploitation of knowledge through partnership with industry and the creation of spinout companies. Bristol is a member of the Worldwide Universities Network and of the Russell Group of major, research-intensive universities in the UK. About ReNeuron ReNeuron is a leading, UK-based stem cell business. Its primary objective is the development of stem cell therapies targeting areas of significant unmet or poorly met medical need. ReNeuron has received regulatory and conditional ethical approvals to commence a Phase I clinical trial in the UK with its lead ReN001 stem cell therapy for disabled stroke patients. The Company is developing stem cell therapies for a number of other conditions, including peripheral arterial disease and diseases of the retina. ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell® products for use in academic and commercial research. The Company's ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Millipore Corporation. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com. This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements. This information is provided by RNS The company news service from the London Stock Exchange END
MSCBCBDBGGBGGCU More |
||
| 22-10-09 | RNS |
|
|
RNS Number : 2388B ReNeuron Group plc 22 October 2009
PRESS RELEASE ReNeuron to present ReN001 stroke programme at Royal Society of Medicine briefing Guildford, UK, 22 October 2009: ReNeuron Group plc (LSE: RENE.L) announces that it will present its approach to the treatment of disabled stroke patients with its ReN001 stem cell therapy at the Royal Society of Medicine's 10th Medical Innovations Briefing to be held in London on the evening of 27 October 2009. The presentation will describe ReNeuron's ReN001 stroke therapy and aspects of the proposed Phase I clinical trial with ReN001, for which UK regulatory and conditional ethical approvals were obtained earlier this year. The briefing will be given by the Principal Investigator for the Phase I trial, Professor Keith Muir, SINAPSE Professor of Clinical Imaging, Division of Clinical Neurosciences at the University of Glasgow, and Dr John Sinden, Chief Scientific Officer of ReNeuron. The proceedings will be filmed and made available via the websites of ReNeuron and the Royal Society of Medicine in due course. Enquiries:
Dr John Sinden, Chief Scientific Officer ReNeuron Group plc
Financial Dynamics
Daniel Stewart & Company plc
Matrix Corporate Capital LLP
Royal Society of Medicine About ReNeuron ReNeuron is a leading, UK-based stem cell business. Its primary objective is the development of stem cell therapies targeting areas of significant unmet or poorly met medical need. ReNeuron has received regulatory and conditional ethical approvals to commence a Phase I clinical trial in the UK with its lead ReN001 stem cell therapy for disabled stroke patients. The Company is developing stem cell therapies for a number of other conditions, including peripheral arterial disease and diseases of the retina. ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell® products for use in academic and commercial research. The Company's ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Millipore Corporation. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com. This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements. This information is provided by RNS The company news service from the London Stock Exchange END
MSCBDBDGRSDGGCD More |
||
| 02-10-09 | RNS |
|
|
RNS Number : 1106A ReNeuron Group plc 02 October 2009
PRESS RELEASE
ReNeuron announces publication of new research using ReNcell® stem cell products Guildford, UK, 2 October 2009: ReNeuron Group plc (LSE: RENE.L) announces the recent publication of new research using its ReNcell® neural stem cell products. These human cell lines and supporting products are marketed through US-based Millipore Corporation for academic and commercial research. Researchers from the University of California, San Diego School of Medicine and the Salk Institute for Biological Studies, La Jolla, California have developed a safe strategy for reprogramming cells to a pluripotent state without the use of the potentially harmful viral delivery mechanisms or genomic insertions that were necessary in earlier cell reprogramming studies conducted elsewhere. In the study, researchers were able to reprogramme ReNeuron's ReNcell®VM cell line using a single factor to generate stable human induced pluripotent stem cells (iPS cells), similar to human embryonic stem cells with the ability to differentiate into any type of cell in the body. The current excitement surrounding iPS cells lies in their potential to circumvent the need to extract such pluripotent stem cells from the early human embryo, as is the case with human embryonic stem cells. The research paper describes the ReNcell®VM cell line used in the study as representing a reliable, homogenous and commercially available tool to dissect the individual factors required for cell reprogramming, and a potentially better standard model for fundamental cell reprogramming studies than human primary fibroblasts, a cell type typically used in this type of research. Moreover, the paper describes the reprogramming strategy used in the study, due to its lack of viral or transgene interference with the cells, as representing a safe way to generate iPS cells for potential clinical use as well as basic research. The research, led by UCSD Stem Cell Program researcher Alysson Muotri, PhD, assistant professor in the Departments of Pediatrics at UC San Diego and Rady Children's Hospital, San Diego and UCSD's Department of Cellular and Molecular Medicine, was published in the on-line journal, PLoS One in September (Marchetto, M.C.N. et al. (2009) PLoS ONE 4(9), e7076). Dr John Sinden, Chief Scientific Officer of ReNeuron, said: "This latest publication is a clear example of how ReNeuron's ReNcell® lines can be successfully used at the very cutting edge of stem cell research. In this study, the ReNcell®VM cell line was proven to be efficient in generating stable iPS cells at a significantly higher frequency than that obtained using human primary fibroblasts. Furthermore, the study showed for the first time that the iPS cells generated carried a transcriptional "signature" of the original ReNcell® donor cells, raising interesting questions as to what effects, if any, this "memory retention" might have. "We are delighted to work with Millipore to make these valuable stem cell research tools available to the scientific community." Enquiries:
Dr John Sinden, Chief Scientific Officer ReNeuron Group plc
Financial Dynamics
Daniel Stewart & Company plc
Matrix Corporate Capital LLP About ReNeuron ReNeuron is a leading, UK-based stem cell business. Its primary objective is the development of stem cell therapies targeting areas of significant unmet or poorly met medical need. ReNeuron has received regulatory and conditional ethical approvals to commence a Phase I clinical trial in the UK with its lead ReN001 stem cell therapy for disabled stroke patients. The Company is developing stem cell therapies for a number of other conditions, including peripheral arterial disease and diseases of the retina. ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell® products for use in academic and commercial research. The Company's ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Millipore Corporation. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com. About Millipore Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, Millipore collaborates with customers to confront the world's challenging human health issues. From research to development to production, Millipore's scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 5,900 employees worldwide. For more information, visit http://www.millipore.com. This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements. This information is provided by RNS The company news service from the London Stock Exchange END
MSCEAFEFEANNFAE More |
||
| 17-09-09 | RNS |
|
|
RNS Number : 2187Z ReNeuron Group plc 17 September 2009
PRESS RELEASE
Results of 2009 Annual General Meeting Guildford, UK, 17 September 2009: ReNeuron Group plc (LSE: RENE) announces that all resolutions put to its shareholders at today's 2009 Annual General Meeting were passed. Enquiries:
Michael Hunt, Chief Executive Officer
Dr John Sinden, Chief Scientific Officer
ReNeuron Group plc
Jonathan Birt, Susan Quigley
Simon Leathers
Alastair Stratton, Tim Graham
About ReNeuron ReNeuron is a leading, UK-based stem cell business. Its primary objective is the development of stem cell therapies targeting areas of significant unmet or poorly met medical need. ReNeuron has received regulatory and conditional ethical approvals to commence a Phase I clinical trial in the UK with its lead ReN001 stem cell therapy for disabled stroke patients. The Company is developing stem cell therapies for a number of other conditions, including peripheral arterial disease and diseases of the retina. ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell® products for use in academic and commercial research. The Company's ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Millipore Corporation. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com. This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements. This information is provided by RNS The company news service from the London Stock Exchange END
RAGUBVWRKRRKARR More |
||
| Date/Time | Subject | Author | ||
|---|---|---|---|---|
| Sat 20:30 | ||||
|
| ||||
|
| ||||
|
Yes, I did, and was not surprised at the polarised views. George Bush played to this for years with his 'moral' opposition to federal funding for stem-cell research which had a lot more to do with vote-hunting than anything else. I thought through the issues before investing in RENE and have no doubts whatever that research which is specifically designed to try to find treatments for very difficult and often life-threatening conditions should be supported and encouraged.
More | View thread (3) | Respond | Login to Vote up | Login to Vote down |
||||
| Fri 12:04 | ||||
|
| ||||
|
| ||||
|
Thanks to those of you who gave some tips. Much appreciated.
I've dipped into a couple and will keep an eye on the others and see how it goes. Will buy more RENE soon, 7.2p not bad but migh wait and see of they dip a little more and pick more up at 7p or hopefully slightly less. As usual.....wait and see.... More | View thread (1) | Respond | Login to Vote up | Login to Vote down |
||||
| Fri 11:35 | ||||
|
| ||||
|
| ||||
|
Sey but not yet wait until after the open offer-could go either way another high risk, but it's in GKP's region- so if the risk pays off omg!
More | View thread (6) | Respond | Login to Vote up | Login to Vote down |
||||
| Fri 10:59 | ||||
|
| ||||
|
| ||||
|
badeli - nice find - did you read the comments to the acticle ?
More | View thread (3) | Respond | Login to Vote up | Login to Vote down |
||||
They have not been approved or issued by Interactive Investor Trading Limited.
Discussion Board Terms & Conditions FSA Market Abuse Fact Sheet
More...